Moderate protection is induced by a chimeric protein composed of leucine aminopeptidase and cathepsin L1 against Fasciola hepatica challenge in sheep

Ortega-Vargas, S; Espitia, Clara; Sahagún-Ruíz, Alfredo; Pàrada, Cristina Maria Garcia de Lima; Balderas-Loaeza, A.; Villa-Mancera, Abel; Quiróz-Romero, H.

doi:10.1016/j.vaccine.2019.04.067

Cited by 19 publications

(10 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, the comparative analysis revealed a decrease of 28.71% in cumulative FEC when group 1 was compared to the positive control. These results coincide with a recent report carried out in sheep with a chimeric protein composed by LAP and CL1 which showed protection expressed as reduction in fluke burden (25.5-46.5%) accompanied by a reduction in faecal egg count (22.7-24.4%) and higher titres of IgG1 and IgG2 [44]. These parasitological results are in accordance with the absence of very severe gross lesions as well as a decrease of 44.90% in moderate to severe gross lesions found in group 1 group in comparison with group 3.…”

Section: Discussionsupporting

confidence: 92%

“…In our study, obtained results are indicative of certain level of protection and agree with previous studies carried out with native cathepsins, where similar indicators were tested [32,44]. Group 1 (cocktail + Montanide ISA 61VG) showed a significant protection in terms of decrease of fluke burden (37.2%).…”

Section: Discussionsupporting

confidence: 91%

“…In sheep, trials have been carried out with native cathepsins, CL1 and CL2 and LAP, both alone and in combination, with a reduction in the parasitic burden of 79% with the mixture of all three [33]. Moreover, the use of chimeric protein LAP + CL1 at different concentrations, induced protection with the maximum dose of the antigen (400 g) in relation to the parasitic burden (46.5%) [44]. These divergences between the level of protection reported and our results might be attributed to major differences in the vaccine formulation used, which may have led to the development of contrasting results in terms of vaccine efficacy.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy of a multivalent vaccine against Fasciola hepatica infection in sheep

Zafra

Buffoni

Pérez–Caballero

et al. 2021

Vet Res

View full text Add to dashboard Cite

In this work we report the protection found in a vaccination trial performed in sheep with two different vaccines composed each one by a cocktail of antigens (rCL1, rPrx, rHDM and rLAP) formulated in two different adjuvants (Montanide ISA 61 VG (G1) and Alhydrogel®(G2)). The parameters of protection tested were fluke burden, faecal egg count and evaluation of hepatic lesions. In vaccinated group 1 we found a significant decrease in fluke burden in comparison to both unimmunised and infected control group (37.2%; p = 0.002) and to vaccinated group 2 (Alhydrogel®) (27.08%; p = 0.016). The lower fluke burden found in G1 was accompanied by a decrease in egg output of 28.71% in comparison with the infected control group. Additionally, gross hepatic lesions found in vaccine 1 group showed a significant decrease (p = 0.03) in comparison with unimmunised-infected group. The serological study showed the highest level for both IgG1 and IgG2 in animals from group 1. All these data support the hypothesis of protection found in vaccine 1 group.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of a multivalent vaccine against Fasciola hepatica infection in sheep

Zafra

Buffoni

Pérez–Caballero

et al. 2021

Vet Res

View full text Add to dashboard Cite

show abstract

“…Numerous studies have reported the potential of these proteins in significantly reducing liver fluke burden, egg output or hepatic damage in cattle [ 12 , 13 ], sheep [ 14 , 15 ] and goats [ 16 , 17 ], as vaccine components. However, there are also examples of vaccine trials where protection has not been achieved, so consistency is an issue to be overcome.…”

Section: Introductionmentioning

confidence: 99%

Identification of protective peptides of Fasciola hepatica-derived cathepsin L1 (FhCL1) in vaccinated sheep by a linear B-cell epitope mapping approach

et al. 2020

View full text Add to dashboard Cite

Background Fasciolosis is one of the most important parasitic diseases of livestock. The need for better control strategies gave rise to the identification of various vaccine candidates. The recombinant form of a member of the cysteine protease family, cathepsin L1 of Fasciola hepatica (FhCL1) has been a vaccine target for the past few decades since it has been shown to behave as an immunodominant antigen. However, when FhCL1 was used as vaccine, it has been observed to elicit significant protection in some trials, whereas no protection was provided in others. Methods In order to improve vaccine development strategy, we conducted a linear B-cell epitope mapping of FhCL1 in sheep vaccinated with FhCL1, FhHDM, FhLAP and FhPrx plus Montanide and with significant reduction of the fluke burden, sheep vaccinated with FhCL1, FhHDM, FhLAP and FhPrx plus aluminium hydroxide and with non-significant reduction of the fluke burden, and in unvaccinated-infected sheep. Results Our study showed that the pattern and dynamic of peptide recognition varied noticeably between both vaccinated groups, and that the regions 55–63 and 77–84, which are within the propeptide, and regions 102–114 and 265–273 of FhCL1 were specifically recognised only by vaccinated sheep with significant reduction of the fluke burden. In addition, these animals also showed significant production of specific IgG2, whereas none was observed in vaccinated-Aluminium hydroxide and in infected control animals. Conclusions We have identified 42 residues of FhCL1 that contributed to protective immunity against infection with F. hepatica in sheep. Our results provide indications in relation to key aspects of the immune response. Given the variable outcomes of vaccination trials conducted in ruminants to date, this study adds new insights to improve strategies of vaccine development.

show abstract

“…27 Combining different antigens, such as cathepsins, with LAP or hemoglobin, or vaccination with a chimeric protein composed of leucine aminopeptidase and cathepsin L1 has not substantially improved vaccine efficacy. 27,28 Despite multiple individual studies showing promising results for various DNA vaccine candidates against fascioliasis in animal models, a systematic review and meta-analysis did not show a significant pooled efficacy for all vaccine candidates against fasciola infection. 29…”

Section: Fasciola Sppmentioning

confidence: 99%

Helminth Vaccines in Ruminants

Claerebout

Geldhof

2020

Veterinary Clinics of North America: Food Animal Practice

View full text Add to dashboard Cite

KEYWORDS Gastrointestinal nematodes Lungworm Liver fluke Vaccines KEY POINTSOnly a few vaccines against parasitic helminths of livestock are currently on the market; namely those against Dictyocaulus viviparus in cattle, Haemonchus contortus in sheep, and the tapeworm Echinococcus granulosus in sheep.Research is ongoing to develop vaccines based on purified or recombinantly expressed worm proteins for Ostertagia ostertagi and Cooperia oncophora in cattle, for Teladorsagia circumcincta and H contortus in sheep, and for Fasciola hepatica in ruminants. Recombinant expression of worm antigens with the correct conformation to induce protective immunity is still a major challenge in vaccine development. Vaccination is likely to be part of integrated worm control, together with other control measures, such as anthelmintic treatments, biological control, and grazing management. Interdisciplinary research, including social sciences, should investigate drivers of farmers' and veterinarians' decision making, to optimize uptake of vaccination by the end users.Vet Clin Food Anim 36 (2020) 159-171

show abstract

Moderate protection is induced by a chimeric protein composed of leucine aminopeptidase and cathepsin L1 against Fasciola hepatica challenge in sheep

Cited by 19 publications

References 40 publications

Efficacy of a multivalent vaccine against Fasciola hepatica infection in sheep

Efficacy of a multivalent vaccine against Fasciola hepatica infection in sheep

Identification of protective peptides of Fasciola hepatica-derived cathepsin L1 (FhCL1) in vaccinated sheep by a linear B-cell epitope mapping approach

Helminth Vaccines in Ruminants

Contact Info

Product

Resources

About